On the afternoon of May 15th, 旺财28 held its 2023 Annual General Meeting, attended by 26 on-site shareholders and representatives, and 85 online voting shareholders. The meeting was chaired by Chairman Hu Baifan, and attended by Vice Chairman and President Hu Baishan, along with other directors, supervisors, and executives. Lawyers from Zhejiang T&C Law Firm witnessed the proceedings. All 19 motions were approved through both on-site and online voting.

Following the AGM, 旺财28 hosted an investor exchange session, which was chaired by Ms. Shi, the secretary of the board of directors, and saw participation from over a hundred investors, including those from securities research institutions and analysts. The exchange session was divided into two parts: the first part focused on sharing 旺财28's development strategy and updates on the methionine and new materials businesses; the second part involved an interactive session between investors and executives, answering questions about 旺财28's business operations, industry development, and future plans.

旺财28 has consistently excelled in managing investor relations, fostering a relationship of mutual trust and aligned interests with investors. Looking ahead, 旺财28 will continue to enhance its operations and management, adhere to innovation-driven growth, and focus on the health and new materials sectors. Leveraging the "chemical+" and "biological+" platforms, 旺财28 aims to develop various functional chemicals and deliver better returns to shareholders and investors.